MASH is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. The degree of fibrosis changes treatment decisions.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
MASH is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. The degree of fibrosis changes treatment decisions. Simple fatty liver on an ultrasound does not prove MASH or eligibility for Rezdiffra or Wegovy’s MASH indication.
Metabolic conditions can contribute to liver fat, inflammation, and scarring. Liver enzymes may be normal despite fibrosis. Weight improvement and laboratory improvement do not prove that scarring has resolved.
Adults with suspected liver fat or fibrosis need assessment of cause, metabolic risk, and severity. The labeled MASH treatments apply to adults with noncirrhotic MASH and F2–F3 fibrosis. Cirrhosis and other liver diseases need distinct care.
Review liver tests, imaging, noninvasive fibrosis assessments, alcohol, viral risks, medicines, and supplements. A clinician may coordinate hepatology and further testing; biopsy is not automatically required for every patient. Discuss nutrition, activity, diabetes and lipid care, and product-specific treatment when appropriate.
Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
Vomiting blood, new confusion or severe abdominal pain needs emergency department care now. Call 911 for confusion, severe breathing difficulty, fainting or unsafe travel. New jaundice or increasing abdominal swelling needs prompt medical assessment. Avoid unreviewed liver-detox supplements. A normal enzyme result is not permission to stop follow-up.
Follow liver and fibrosis assessment, metabolic goals, and medicine safety with the treating team. Rezdiffra and Wegovy combination decisions need individualized review. The trials and labels do not establish that a combination is appropriate for everyone.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Not everyone needs a biopsy. The clinician reviews blood tests, imaging, noninvasive fibrosis assessments, and uncertainty in the diagnosis. A biopsy may be recommended when it will affect diagnosis or treatment. Bring any previous fibrosis or biopsy records.
No. Liver fat on imaging does not by itself establish noncirrhotic MASH with F2–F3 fibrosis. The clinician reviews diagnosis, severity, and other causes before deciding whether Rezdiffra or Wegovy injection’s MASH indication fits.
No. The Wegovy MASH indication belongs to the injection. Wegovy tablets have adult weight and qualifying cardiovascular indications, not the injection’s MASH indication. Product choice must follow the exact formulation’s label.
A clinician must review the liver diagnosis, fibrosis stage, metabolic needs, side effects, and interactions before combining Rezdiffra with a GLP-1 medicine. The labels do not establish that every patient should use the combination. Keep specialist follow-up and do not add or switch treatments yourself.
No. Improved weight or normal liver enzymes does not prove that fibrosis has resolved. Keep the clinician’s liver and fibrosis follow-up plan. Tests and symptoms are interpreted together.
Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
MASH means metabolic dysfunction-associated steatohepatitis: fat buildup in the liver is accompanied by inflammation and liver-cell injury. Insulin resistance, type 2 diabetes, excess body weight, abnormal blood fats and inherited factors can contribute, although researchers are still studying why some people develop inflammation and scarring. MASH can occur without obvious symptoms. Liver fat alone does not establish the amount of fibrosis, and alcohol, medicines or other liver diseases may also need assessment. A clinician reviews the cause and stage before selecting treatment.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
